CareDx (CDNA)

• Market cap: $939M
• 1 day: -3.86%
• 5 days: -12.00%
• 1 month: -12.32%
• 3 months: -25.37%
• 6 months: -27.82%
• Year to date: -21.28%
• 1 year: 107.34%
• 5 years: -24.31%
• 10 years: 232.16%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Employees: 650

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

78% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 50

49% more call options, than puts

Call options by funds: $763K | Put options by funds: $512K

0.86% more ownership

Funds ownership: 97.91% [Q3] → 98.77% (+0.86%) [Q4]

5% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 43

3% less funds holding

Funds holding: 215 [Q3] → 208 (-7) [Q4]

30% less capital invested

Capital invested by funds: $1.61B [Q3] → $1.13B (-$477M) [Q4]

40% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 3 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 48% upside
• Avg. target: $30 79% upside
• High target: $40 136% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Goldman Sachs Matthew Sykes 41% 1-year accuracy 14 / 34 met price target	53% upside $26	Buy Maintained	17 Apr 2025
HC Wainwright & Co. Yi Chen 28% 1-year accuracy 48 / 172 met price target	48% upside $25	Neutral Maintained	3 Mar 2025
Stephens & Co. Mason Carrico 12% 1-year accuracy 3 / 26 met price target	136% upside $40	Overweight Reiterated	27 Feb 2025